Embedded Files
THE ROLE OF INTRAVITREAL BEVACIZUMAB ON CYSTOID MACULAR EDEMA
THE ROLE OF INTRAVITREAL BEVACIZUMAB ON CYSTOID MACULAR EDEMA
Bakhtiar Qadir Hamasalh a, Tablo Ahmed Mirza b, and Fazil Ahmad Abdulla c
Bakhtiar Qadir Hamasalh a, Tablo Ahmed Mirza b, and Fazil Ahmad Abdulla c
a Department of Surgery, Ophthalmology College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
b Shaheed Dr. Aso Teaching Eye Hospital, Kurdistan Region, Iraq.
c Department of Community Medicine, College of Medicine, University of Sulaimani Kurdistan Region, Iraq.
Submitted: 23/2/2020; Accepted: 11/2/2021; Published: 21/6/2021
DOI Link: https://doi.org/10.17656/jsmc.10302
ABSTRACT
Background
Cystoid macular edema (CME) is an intracellular accumulation of fluid in the retinal layers around the fovea; it contributes to reducing visual acuity by altering the functional cell relationship in the retina.
Objectives
To detect the role of intravitreal Bevacizumab (Avastin) on decreasing central retinal thickness in patients with cystoid macular edema.
Materials and Methods
In a prospective study in Shaheed Dr. Aso Eye Hospital in As-Suleimanyah city, 65 patients with macular edema by Ocular coherent tomography (OCT) included, after a single intravitreal avastin injection, we repeated the OCT after 2 weeks & 3 months after the injection.
Results
Central retinal thickness was greatly decreased in Diabetic patients and CRVO during the follow-up period, but a lesser effect was seen in BRVO. The immediate response was seen in ARMD after 2 weeks. Central retinal thickness decreased more in those patients who received Avastin alone than patients treated by Avastin with Laser photocoagulation. There was no significant improvement of visual acuity in the patients after IVTA injection
Conclusion
Avastin is an effective drug in decreasing central retinal thickness and delaying its complications mostly in patients with Diabetic retinopathy and CRVO, and reduces the need for LASER therapy in these patients.
KEYWORDS
Intravitreal, Bevacizumab, Diabetic retinopathy, Avastin.
References
1. Coscas G, Cunha-Vaz J, Soubrane G. Macular edema: definition and basic concepts. Developments in ophthalmology. 2010;47(10):1-9.
2. Lanzugorta-aresti A, Palacios-Pozo E, MenezoRozalin JL. Prevention of vision loss after cataract surgery in diabetic macular edema with IVTA. Retina2009;29(4):530-5
3. Stahl A, Agostini H, Hansen LL. Bevacizumab in retinal vein occlusion. Result of prospective case series. Graetes Arch ClinOphthalmol. 2007;14(9):141-9.
4. Coscas G, Cunha-Vas J, Sourbrane G. Hospital Intercommunal de Creteil, service Universtaire d opthalmogie. Creteil, Paris: Karger AG Basal; 2006;70(1):34–48
5. El-Batarny AM. Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. ClinOphthalmol. 2007;27(2):149-155.
6. Fu A, Bui A, Roe R, Ahmed I, Ai E. Myron Yanoff and Jay`s Duker Ophthalmology2008;108(2):765-72.
7. Bertram G.Katzung, Susan B.MastersS, J.Trevor A. Basic and clinical pharmacology. 2012;12:991-5.
8. Hollands H, Wong J, Bruen R. Short term intra ocular pressure change after IVTA injection. Can ophthalmol. 2007;42(11):807-11.
9. Mentes j, Erakgun T, Afrashi F, Kerci G. Incidence of cystoids macular edema after uncomplicated phacoemulsification. Ophthalmologica. 2003;(217):408-12
10. Norregeaard JC, Bernth-Petersen P, Bellan L Intraoperative clinical practice and risk of early complications after cataract extraction in the United states, Canada, Denmark, and Spain. Ophlamology. 1999;(106):42-8.
11. Kova-evi D, aljku-Mance T. intra vitrealbivacizumab for the management of ARMD. Antropol. 2008;32(2):5-7.
12. Cordero Coma M, Sobrin L, Onal S. Intravitrealavastin for treatment of uveitic macular edema. Ophthalmology. 2007;14(7):1201-8.
13. MoldowBsander M. The effect of acetazolamide on passive and active transport of fluorescent across the blood – rerinal barrier in retinitis pigmentosa complicated by macular edema. Graefes Arch clin EXP Opthalmol1998;105(9):881-889.
14. Soheilian M, Ramezani A, Obudi A, Yaseri M, Ah madieh H. Randomized trial of intravitreal bevacizumab alone or combined with macular photo coagulation in diabetic macular edema. Ophthalmology. 2009;116(6):1142-1150
15. Goff MJ, Jumper JM, Yang SS. Intravitrealtriamcinilonacetonide treatment of macular edema associated with CRVO. Retina. 2006; 26:896-901.
16. Spitzer MS, Ziemssen F, Yoeruek E. Efficacy of intravitreal bevacizumab in treating post-operative pseudophakic CME. J cataract Refract surgery. 2008;34(1):70-5
17. Campochiaro PA, Hafiz G, Shah SM, Nguyen. bevacizumab for macular edema due to retinal vein occlusion, implication of VEGF as critical stimulator. MolTher.2008;16(4):791-9
18. Martin DF, Maguire MG, Ying GS, Grunwald, JE, Jaffe, GJ. Ranibizumab and Bevacizumab for neovascular age related macular degeneration. New England journal of medicine 2011;364 (20):1897-1908
19. Shima C, Sakaguchi H, Gomi F. Complication in patients after intravetrial injection of bevacizumab. ActaOpthalmological.2008;86:372-376.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Page updated
Report abuse